10,913 reports of this reaction
3.1% of all LEVONORGESTREL reports
#5 most reported adverse reaction
GENITAL HAEMORRHAGE is the #5 most commonly reported adverse reaction for LEVONORGESTREL, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 10,913 FDA adverse event reports linking LEVONORGESTREL to GENITAL HAEMORRHAGE. This represents approximately 3.1% of all 357,584 adverse event reports for this drug.
Patients taking LEVONORGESTREL who experience genital haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GENITAL HAEMORRHAGE is moderately reported among LEVONORGESTREL users, representing a notable but not dominant share of adverse events.
In addition to genital haemorrhage, the following adverse reactions have been reported for LEVONORGESTREL:
GENITAL HAEMORRHAGE has been reported as an adverse event in 10,913 FDA reports for LEVONORGESTREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
GENITAL HAEMORRHAGE accounts for approximately 3.1% of all adverse event reports for LEVONORGESTREL, making it a notable side effect.
If you experience genital haemorrhage while taking LEVONORGESTREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.